GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...
The significantly longer half-life of Flyrcado (109 minutes) allows for it to be manufactured at an offsite pharmacy and delivered as a ready-to-use unit dose. The approval was supported by data from ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland (Reuters) - The U.S. Food and Drug Administration ...
GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission ...
ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has delivered the first patient doses of Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission ...
GE HealthCare Technologies, Inc. GEHC announced that it has received FDA approval for Flyrcado (flurpiridaz F 18), a breakthrough positron emission tomography myocardial perfusion imaging (PET MPI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results